Related Experiment Videos
[Therapeutic plasmapheresis and alpha-tocopherol in patients with coronary heart disease]
Insights
Therapeutic plasmapheresis (TP) effectively lowers cholesterol in coronary heart disease patients. Adding alpha-tocopherol (AT) enhances and prolongs these hypolipidemic effects, improving antioxidant status.
Area of Science:
- Cardiology
- Biochemistry
- Internal Medicine
Background:
- Coronary heart disease (CHD) frequently coexists with hypercholesterolemia.
- Managing dyslipidemia is crucial for reducing cardiovascular events.
Purpose of the Study:
- To evaluate the hypolipidemic effectiveness of therapeutic plasmapheresis (TP) combined with alpha-tocopherol (AT) in CHD patients.
- To assess the impact on lipid peroxidation and antioxidant systems.
Main Methods:
- 46 patients with CHD and hypercholesterolemia underwent TP combined with AT.
- Clinical status, lipid profile, lipid peroxidation, and ceruloplasmin levels were monitored over 3 months.
Main Results:
- TP demonstrated significant hypolipidemic effects within 2-3 weeks, reducing lipid peroxidation.
- The addition of AT prolonged the hypolipidemic action of TP.
- AT promoted enhanced plasma antioxidant potential, including increased HDL and stabilized ceruloplasmin.
Conclusions:
- TP is a highly effective hypolipidemic treatment for hypercholesterolemic CHD patients.
- Combined AT administration extends TP's benefits and improves antioxidant capacity.
Abstract:
46 patients with coronary heart disease with hypercholesterolemia were exposed to therapeutic plasmapheresis (TP) in combination with alpha-tocopherol treatment (AT). The results of 3-month follow-up with assessment of the clinical status, lipid spectrum, lipid peroxidation, concentration of ceruloplasmin indicated high hypolipidemic effectiveness of TP 2-3 weeks after the treatment as shown by inhibition of lipid peroxidation and antioxidant system. The addition of AT prolonged the hypolipidemic effect of TP, promoted optimization of plasma antioxidant potential (a rise in HDL, stabilization of ceruloplasmin levels).